- Details
- Edmond Kwan discusses his latest research on circulating tumor DNA (ctDNA) as a predictive marker for response to Lutetium PSMA-617 versus cabazitaxel. The Phase II TheraP trial compared these treatments in patients with advanced metastatic castration-resistant prostate cancer, utilizing dual imaging selection. Dr. Kwan highlights that ctDNA fraction, the proportion of tumor-derived DNA in circula...
|
- Details
- Andrea Miyahira speaks with Catherine Nam about her paper, "The Future is Female: Urology Workforce Projection from 2020 to 2057," published in Urologic Clinics of North America. Dr. Nam addresses the critical issue of the urologic workforce shortage, driven by factors like aging practitioners and limited residency slots due to the Balanced Budget Act of 1997. As the demand for urologic care is se...
|
- Details
- Ping Mu discusses his team's paper, "ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity in AR-Targeted Therapy Resistance in Prostate Cancer," published in Cancer Discovery. Dr. Mu explains that while primary prostate cancer can be managed effectively, resistance to androgen receptor (AR)-targeted therapies in metastatic cases remains a significant challenge. His research identifies the zin...
|
- Details
- Andrea Miyahira interviews Estefania Labanca about her team's work, featured in the paper "Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-Derived Xenograft Series." Dr. Labanca highlights the MD Anderson Prostate Cancer Patient-Derived Xenograft (MDA PCa PDX) Program, a pioneering effort started over 30 years ago by Dr. Navone to model lethal prostate cancer, especially...
|
- Details
- Andrea Miyahira hosts Tanya Stoyanova to discuss her study, published in Cell Reports Medicine, on UCHL1 as a potential biomarker and therapeutic target for neuroendocrine carcinomas, including neuroendocrine prostate cancer. Dr. Stoyanova explains that UCHL1, which has dual functions in protein stability, is highly expressed in neuroendocrine tumors and not in non-neuroendocrine ones. The study f...
|
- Details
- Isla Garraway discusses her team's study that explores how neighborhood deprivation, race, and ethnicity impact prostate cancer outcomes across California healthcare systems. Dr. Garraway highlights the significant disparities in prostate cancer incidence and outcomes, particularly among Black men and those in deprived neighborhoods. The study compares outcomes between veterans treated in the VA s...
|
- Details
- Andrea Miyahira engages with Jelani Zarif regarding his team’s paper elucidating the metabolic reprogramming of tumor-associated macrophages utilizing the potent glutamine antagonist JHU083. Their dialogue explores the intricate mechanisms underpinning glutamine metabolism within tumor cells and macrophages, unveiling the transformative impact of JHU083 on macrophage functionality. Dr. Zarif artic...
|
- Details
- Diane Newman interviews Siobhan Sutcliffe about a project funded as part of the White House Moonshot Initiative. This project aims to gather more data to support PSA-based risk-stratified screening for prostate cancer. By using a man's PSA value, the research seeks to determine whether he might develop clinically significant prostate cancer that could potentially shorten his lifespan. The study in...
|
- Details
- Andrea Miyahira discusses a study on noninvasive detection of neuroendocrine prostate cancer with Himisha Beltran and Francesca Demichelis. Their collaborative paper, published in Cancer Discovery, introduces a targeted cell-free DNA methylation panel called NEMO (Neuroendocrine Monitoring). This panel aims to distinguish neuroendocrine prostate cancer from adenocarcinoma using DNA methylation pat...
|
- Details
- Rana McKay discusses her team’s study on the HSD3B1 gene and its link to prostate cancer outcomes, published in JAMA Network Open. The study focuses on the adrenal-permissive allele of HSD3B1, which influences the body's conversion of DHEA to potent androgens, affecting responses to hormonal therapy and prostate cancer progression. Dr. McKay explains that this genetic variant shows variable preval...
|
